PDCD1 and non-small cell lung carcinoma: The use of anti-PD-1 or anti-PD-L1 antibodies after radiation therapy may contribute to increasing the effectiveness of immunotherapy in patients with non-small cell lung cancer and to prolonging overall survival (OS) and progression free survival (PFS) [15].